1. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

The JAK2 mutation JAK2V617F is found frequently in patients with myeloproliferative disorders (MPD) and transforms hematopoietic cells to cytokine-independent proliferation when expressed with specific cytokine receptors. The Src homology 2 (SH2) and pleckstrin homology (PH) domain-containing adaptor protein Lnk (SH2B3) is a negative regulator of hematopoiet

The Society for Leukocyte Biology.

2. Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan

A unique mutation of the JAK2 gene, V617F, has recently been identified in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. To determine the relevance of this mutation in other types of hematological neoplasms in Japan, we performed allele-specific polymerase chain reaction analysis on the JAK2 gene. The V617F mutation

Genetics and Molecular Biology. Publicado em: 2008

3. Expressão genica global e estudo do gene JUNB em policitemia vera / Global gene expression and study of the JUNB gene in polycythemia

Polycythemia vera (PV) is a chronic myeloproliferative disorder that arises through clonal proliferation of multipotent hematopoietic progenitors. PV patients present bone marrow trilineage expansion, leading to increased production of mature red cells, granulocytes and platelets. Important PV features are elevated red cell mass, despite normal or subnormal

Publicado em: 2007

4. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia

BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon 12 and MPL W515K/L, besides chromosomal abnormalities. Furthermore, molecular and cytogenetic alterations

Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-12

5. A mutação JAK2 V617F e as síndromes mieloproliferativas

Síndromes mieloproliferativas (SMPs) são doenças hematopoéticas de origem clonal que apresentam amplificação de uma ou mais linhagens mielóides. Policitemia vera (PV), trombocitemia essencial (TE), mielofibrose idiopática (MF) e leucemia mielóide crônica (LMC) são consideradas SMPs clássicas e apresentam características clínicas e biológicas c

Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2008

6. Estudo citogenético e pesquisa de mutações nos genes JAK2 e MPL em Policitemia vera, Mielofibrose primária e Trombocitemia essencial / Cytogenetic study and search for mutations in JAK2 and MPL genes in Polycythemia vera, Primary myelofibrosis and Essential thrombocythemia

Objetivos: Descrever as alteracoes cromossomicas em policitemia vera (PV), trombocitemia essencial (TE) e mielofibrose primaria (MF). Verificar se a taxa de anormalidades cromossomicas e ampliada pela FISH nos casos com cariotipo normal e ausencia de metafases. Detectar a incidencia da mutacao JAK2 V617F em PV, TE e MF; de mutacoes no exon 12 do JAK2 em PV e

Publicado em: 2010

7. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome

Patients with myeloproliferative disorders are at a high risk of developing thrombotic events. Several investigators have hypothesized that endothelial cell (EC) abnormalities might contribute to this prothrombotic state. Budd-Chiari syndrome (BCS) and portal vein thrombosis have been reported to be associated with JAK2V617F-positive hematopoiesis. We explor

American Society of Hematology.

8. The JAK2 V617F mutation in Philadelphia‐negative chronic myeloproliferative disorders

BMJ Group.

9. Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) are a group of closely related stem-cell-derived clonal proliferative diseases. Most cases are sporadic but first-degree relatives of MPN patients have a five- to seven-fold increased risk for developing an MPN. The tumors of most patients carry a mutation in the Janus kinase 2 gene (JAK2V617F). Recently, three groups have

BioMed Central.

10. JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia

Polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) are myeloproliferative disorders (MPD) that arise from the clonal proliferation of a pluripotent hematopoietic progenitor, leading to the overproduction of one or more myeloid lineages. Recently, a specific mutation in the JAK2 gene, which encodes a tyrosine kinase, has

Genetics and Molecular Biology. Publicado em: 2007-03

11. Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms

Chronic myeloproliferative neoplasms arise from clonal proliferation of hematopoietic stem cells. According to the World Health Organization myeloproliferative neoplasms are classified as: chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, hypereosin

Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011

12. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview

ABSTRACTMyeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis in a subgr

Rev. Bras. Hematol. Hemoter.. Publicado em: 2015-10